# Arsenal Capital Partners

> Arsenal Capital Partners is a VC fund backing Health Care and Biotechnology. See 13 investments, round sizes, portfolio and contact details. Updated Oct 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 13
- Last investment: Sep 2024
- Lead investor: 77%
- Fund size: $1.1B
- Last fund: Aug 2022
- Last updated: Oct 2026
- Website: http://arsenalcapital.com

Arsenal Capital Partners is a private equity firm that offers investment services to middle-market industrial and healthcare companies. It was founded in 2000 and is based in New York.

## Contacts

5 contacts available for Arsenal Capital Partners. Shizune tracks 11 team members at Arsenal Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/arsenal-capital-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 7 | 54% |
| Biotechnology | 5 | 38% |
| Pharmaceutical | 3 | 23% |
| Medical | 2 | 15% |
| Hospital | 2 | 15% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Private Equity | 3 | 23% |
| Seed | 1 | 8% |
| Series A | 1 | 8% |
| Series F | 1 | 8% |
| Series G | 1 | 8% |

8 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Aaron Wolfe | Partner | 0 | — |
| Brian Orkin | Investment Partner | 0 | — |
| Denis Getsios | Senior Vice President, Applied Analytics | 0 | — |
| Eugene Gorbach | Investment Partner | 0 | — |
| Jeffrey Kovach | MD | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| hc1 | hc1 Insights™ (hc1) is the leader in identifying real-time insights and risk signals in complex laboratory data. hc1 solutions empower thousands of laboratory locations to leverage the insights within their own data to optimize operations and inform testing and treatment decisions for millions of patients. Over more than a decade our flagshipsolutions have helped us forge a broad set of lab and health system partnerships with their ability to unlock actionable, real-time insights to increase efficiency and reduce costs. hc1 continues to develop new solutions that bring us closer to achieving our mission: Right Patient. Right Test. Right Prescription. To learn more about our proven approach, visit www.hc1.com. | $6.5M | Venture - Series Unknown | Sep 11, 2024 | http://www.hc1.com |
| Epic Sciences | Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with anumber of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health. | $24M | Series G | Apr 14, 2023 | http://www.epicsciences.com |
| Certara | Certara is the global leader in biosimulation. It accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries. Certara'send-to-end platform includes biosimulation, regulatory science, and market access solutions. It integrates its unique portfolio of software and technology-enabled services spanning discovery to post-approval. | $449M | Post-IPO Secondary | Nov 07, 2022 | https://www.certara.com |
| Epic Sciences | Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with anumber of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health. | $43M | Series F | Jun 01, 2022 | http://www.epicsciences.com |
| OncoHealth | OncoHealth is a leading digital health company dedicated to helping health plans, employers, providers, patients, and life science researchers navigate the physical, mental and financial complexities of cancer through technology enabled services and real-world data analytics. Supporting more than 7 million people in the US and Puerto Rico,OncoHealth offers digital solutions for treatment review, real-world evidence, and virtual care across all cancer types. |  | Private Equity | May 09, 2022 | https://oncohealth.us |
| WCG | WCG accelerates the development of new medical therapies by improving the conduct and quality of clinical trials. We do this through our industry-wide platform that connects all stakeholders in the clinical trial process, and by expanding access and awareness for clinical trials to all health care providers and their patients. |  | Private Equity | Nov 14, 2019 | http://www.wcgclinical.com/ |
| BioIVT | Headquartered in Westbury, NY, BioIVT is the leading provider of biological and in vitro products to the biopharmaceutical, diagnostic, and biotechnology organizations. BioIVT’s products are used in drug discovery, biomarker, toxicology, bioanalytical, and ADME research. The company’s products and value added services enable its clients tosignificantly reduce the time and expense of bringing new drugs and diagnostics to market. |  |  | Oct 13, 2016 | https://bioivt.com |
| Aptimmune | Aptimmune is a biotechnology company that focuses on developing a muscoal vaccine against viral diseases swine. It focuses on swine vaccines and the prevention of two major diseases, Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and influenza. It utilizes novel technologies to create effective nasal delivery vaccines against PRRSVsuch as the proprietary pig alveolar macrophage cell line ZMAC.The company was founded in 2010 and headquartered in St. Louis, Missouri. | $2.8M | Series A | Mar 24, 2016 | http://www.aptimmune.com/ |
| Juristat | Juristat transforms public patent data into actionable analytics to help firms and in-house counsel optimize patent prosecution strategies.Our Examiner Report analyzes past behaviors of all USPTO patent examiners to predict their future behavior. Using our reports, counsel can increase allowance rates, decrease time to allowance, and reducecosts by avoiding unnecessary and statistically inefficient and ineffective strategies, particularly when determining how to best respond to an adverse office action.We can filter results by individual examiners, art units, assignees, application types, and claims. Furthermore, we can show changes in behavior over time.Our continually growing database includes complete image file wrappers for over 5.5 million patent applications, as well as 99% of all active art units (over 900 in total) and active examiners (over 8,000 in total). | $1.2M | Seed | Jan 05, 2015 | http://juristat.com |
| TractManager |  |  | Private Equity |  |  |

10 of 13 investments shown.

## Co-investors
- [Blue Ox Healthcare Partners](https://shizune.co/investors/profile/blue-ox-healthcare-partners) — VC Fund, 3 deals together
- [LabCorp](https://shizune.co/investors/profile/laboratory-corporation-of-america) — VC Fund, 3 deals together
- [Deerfield](https://shizune.co/investors/profile/deerfield) — VC Fund, 2 deals together
- McKesson — VC Fund, 2 deals together
- A1 Health Ventures — VC Fund, 1 deal together
- [Deerfield Capital Management](https://shizune.co/investors/profile/deerfield-management) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund
- [Maven Capital Partners](https://shizune.co/investors/profile/maven-capital-partners) — VC Fund
- [Foresight Group](https://shizune.co/investors/profile/foresight-group) — VC Fund

## FAQ

### What does Arsenal Capital Partners invest in?

Arsenal Capital Partners invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Private Equity and Seed stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Arsenal Capital Partners?

Public channels for Arsenal Capital Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Arsenal Capital Partners?

The team at Arsenal Capital Partners includes Aaron Wolfe (Partner), Brian Orkin (Investment Partner) and Denis Getsios (Senior Vice President, Applied Analytics), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co